<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03826628</url>
  </required_header>
  <id_info>
    <org_study_id>DSLP-01</org_study_id>
    <nct_id>NCT03826628</nct_id>
  </id_info>
  <brief_title>Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex</brief_title>
  <official_title>A Phase 2/3, Multi-Center, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Response Comparison of the Efficacy and Safety of a Topical Rapamycin Cream for the Treatment of Facial Angiofibromas (FA) Associated With Tuberous Sclerosis Complex (TSC) in Patients 6 Years of Age and Over</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dermatology Specialties Limited Partnership</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dermatology Specialties Limited Partnership</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to compare the safety and efficacy of two different strengths of Rapamycin&#xD;
      cream, topical and placebo over 26 weeks in the treatment of facial angiofibroma (FA)&#xD;
      associated with Tuberous Sclerosis Complex (TSC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Topical rapamycin has previously been used to treat FA associated with TSC, reducing&#xD;
      erythema, papule size, while flattening lesions and improving skin texture. Topical rapamycin&#xD;
      has been reported to be well tolerated.&#xD;
&#xD;
      The efficacy and safety of a topical rapamycin cream at two strengths (0.5% and 1.0%) will be&#xD;
      assessed during a 26 week double-blind treatment phase with assessments made at clinical&#xD;
      visits at baseline, 2, 8, 14, 20 and 26 weeks, and at follow-up (4 weeks after the last dose&#xD;
      of study drug).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 28, 2019</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants obtaining successful treatment</measure>
    <time_frame>After 26 weeks treatment</time_frame>
    <description>Success on the Investigator Global Assessment (IGA) scale is defined as clear or almost clear with an improvement of at least two grades from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to treatment success</measure>
    <time_frame>From first dose to 26 weeks</time_frame>
    <description>The time elapsed from the first dose to the time of treatment success, according to the IGA scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in IGA</measure>
    <time_frame>At baseline and after 26 weeks treatment</time_frame>
    <description>The change in grading on the IGA scale from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in FASI</measure>
    <time_frame>At baseline and after 26 weeks treatment</time_frame>
    <description>The change in grading on the Facial Angiofibroma Severity Index (FASI) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective (participant or parent/caregiver) improvement rating</measure>
    <time_frame>After 26 weeks treatment</time_frame>
    <description>Percentage improvement in FA since beginning treatment, as assessed by the participant or parent/caregiver</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective (clinician) improvement rating</measure>
    <time_frame>After 26 weeks treatment</time_frame>
    <description>Percentage improvement in FA since beginning treatment, as assessed by the clinician</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Categorical Change in FA</measure>
    <time_frame>After 26 weeks treatment</time_frame>
    <description>Change in FA since beginning treatment on a 5-point scale, as assessed by the participant or parent/caregiver</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Facial Angiofibroma</condition>
  <condition>Tuberous Sclerosis</condition>
  <arm_group>
    <arm_group_label>0.5% Rapamycin cream, topical</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rapamycin cream topical, 0.5% w/w, applied once daily before bed on affected area for 26 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.0% Rapamycin cream, topical</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rapamycin cream topical, 0.5% w/w, applied once daily before bed on affected area for 26 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo cream topical, applied once daily before bed on affected area for 26 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rapamycin</intervention_name>
    <description>Apply to the affected area once a day, approximately half an hour before retiring for bed in the evening, for 26 weeks</description>
    <arm_group_label>0.5% Rapamycin cream, topical</arm_group_label>
    <arm_group_label>1.0% Rapamycin cream, topical</arm_group_label>
    <other_name>sirolimus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Apply to the affected area once a day, approximately half an hour before retiring for bed in the evening, for 26 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female patients aged ≥ 6 years and ≤ 65 years on the day informed consent is&#xD;
             obtained&#xD;
&#xD;
          2. Patients diagnosed with TSC based on the clinical diagnostic criteria of International&#xD;
             Tuberous Sclerosis Complex Consensus Conference 2012 and presenting visible facial&#xD;
             angiofibroma&#xD;
&#xD;
          3. An FA severity score of 2 or 3 on the IGA scale&#xD;
&#xD;
          4. Patients or their legal representatives capable of understanding the explanation of&#xD;
             the clinical trial and who give written informed consent for participation&#xD;
&#xD;
          5. Patients or their legal representatives able to maintain patient diaries following the&#xD;
             instructions of the investigator or sub-investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who cannot carry out the treatment plan or follow-up assessment&#xD;
&#xD;
          2. Patients with serious skin lesions such as erosions or ulcers&#xD;
&#xD;
          3. Patients with known hypersensitivity to any component of the study product&#xD;
&#xD;
          4. Patients who have received rapamycin/sirolimus, everolimus, or temsirolimus within 3&#xD;
             months of enrolment&#xD;
&#xD;
          5. Patients who received laser therapy or surgical therapy within 6 months prior to trial&#xD;
             enrolment&#xD;
&#xD;
          6. Patients who participated in any other clinical trial within 3 months prior to the day&#xD;
             of enrolment&#xD;
&#xD;
          7. Patients judged unsuitable for this clinical trial by the investigator or&#xD;
             sub-investigator&#xD;
&#xD;
          8. Pregnant or lactating females&#xD;
&#xD;
          9. Sexually active females of childbearing potential not using adequate contraception and&#xD;
             sexually active males not using adequate contraception&#xD;
&#xD;
         10. Patients with immune dysfunction or receiving any form of immunosuppression&#xD;
&#xD;
         11. Patients with severe FA, with a score of 4 on the IGA scale&#xD;
&#xD;
         12. Patients with an FA severity score of less than 2 on the IGA scale&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ioana Stanescu</last_name>
    <role>Study Director</role>
    <affiliation>Dermatology Specialties Limited Partnership</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Phillip Aitken, PhD</last_name>
    <phone>+ 64 9 488 0232</phone>
    <phone_ext>764</phone_ext>
    <email>paitken@aftpharm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kellie Badger</last_name>
      <email>kbadger@phoenixchildrens.com</email>
    </contact>
    <investigator>
      <last_name>Harper Price</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Israel Andrews</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caitlin Knight</last_name>
      <email>caknight@health.ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Doris Trauner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>All Children's Research Institute</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivanna Leon</last_name>
      <phone>727-767-3987</phone>
      <email>ileon3@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Stacie Stapleton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher L Russell</last_name>
      <email>christopher.russell@spectrumhealth.org</email>
    </contact>
    <investigator>
      <last_name>Steven DeRoos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacy Thompson</last_name>
      <email>src2h@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Derek Bauer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Health Queensland</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Neylan</last_name>
      <phone>07 3069 7267</phone>
      <email>melissa.neylan@health.qld.gov.au</email>
    </contact>
    <investigator>
      <last_name>Kate Riney</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Brno</name>
      <address>
        <city>Brno</city>
        <zip>5HG9+4W</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Radek Zizka</last_name>
      <email>rzizka@hungarotrial.com</email>
    </contact>
    <investigator>
      <last_name>Blanka Pinková</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bethesda Children's Hospital of the Hungarian Reformed Church</name>
      <address>
        <city>Budapest</city>
        <zip>G39Q+49</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikoletta Gyarmati</last_name>
      <email>nikoletta.gyarmati@coordination.hu</email>
    </contact>
    <contact_backup>
      <last_name>Hangyal Tamás</last_name>
      <email>Tamas.Hangyal@coordination.hu</email>
    </contact_backup>
    <investigator>
      <last_name>Andras Fogarasi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pécs</name>
      <address>
        <city>Pécs</city>
        <zip>H-7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Czucz</last_name>
      <email>czucz.diana@pte.hu</email>
    </contact>
    <contact_backup>
      <last_name>Annamaria Vass</last_name>
      <email>vass.annamaria@pte.hu</email>
    </contact_backup>
    <investigator>
      <last_name>Kinga Hadzsiev</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Szeged</name>
      <address>
        <city>Szeged</city>
        <zip>64WX+W2</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Várady Szilvia</last_name>
      <email>szilvia.varady.clincoord@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Paczuk Nikolett</last_name>
      <email>nikolett.paczuk.clincoord@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Lajos Kemeny</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Canterbury District Health Board</name>
      <address>
        <city>Christchurch</city>
        <state>Canterbury</state>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malina Storer</last_name>
      <phone>+64 3 364 1157</phone>
      <email>malina.storer@cdhb.health.nz</email>
    </contact>
    <investigator>
      <last_name>Caroline Mahon, FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinic of Neurology and Psychiatry for Children and Youth</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jasna Jancic</last_name>
      <phone>+381 11 265 8355</phone>
    </contact>
    <investigator>
      <last_name>Jasna Jancic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Serbia</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milos Nikolic</last_name>
      <phone>+381 11 366 2465</phone>
    </contact>
    <investigator>
      <last_name>Milos Nikolic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Narodný ústav detských chorȏb</name>
      <address>
        <city>Bratislava</city>
        <zip>83340</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaroslava Payerova</last_name>
      <email>payerova@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Patricia Balazova</last_name>
      <email>pat.balazova@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jaroslava Payerova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Zaragozá</last_name>
      <email>ezaragoza@unav.es</email>
    </contact>
    <contact_backup>
      <last_name>Virginia Blasco</last_name>
      <email>mblascos@unav.es</email>
    </contact_backup>
    <investigator>
      <last_name>Leyre Aguado</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pedro Redondo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mar Garcia</last_name>
      <phone>913531920</phone>
      <phone_ext>7574</phone_ext>
      <email>mgarciai@unav.es</email>
    </contact>
    <investigator>
      <last_name>Marta Ivars</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi-Hua Liao</last_name>
      <phone>+886-2-2312-3456</phone>
      <phone_ext>65317</phone_ext>
      <email>yihualiao@ntu.edu.tw</email>
    </contact>
    <investigator>
      <last_name>Yi-Hua Liao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Czechia</country>
    <country>Hungary</country>
    <country>New Zealand</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 29, 2019</study_first_submitted>
  <study_first_submitted_qc>January 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2019</study_first_posted>
  <last_update_submitted>September 19, 2021</last_update_submitted>
  <last_update_submitted_qc>September 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberous Sclerosis</mesh_term>
    <mesh_term>Angiofibroma</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Facies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual Participant Data is not planned to be shared with other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

